<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EE34007E-A8DD-4B0A-81BF-56D38AB47C32"><gtr:id>EE34007E-A8DD-4B0A-81BF-56D38AB47C32</gtr:id><gtr:name>Institute of Cancer Research</gtr:name><gtr:address><gtr:line1>123 Old Brompton Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>SW7 3RP</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7A730DEF-84E6-45A2-A538-C233A004DF60"><gtr:id>7A730DEF-84E6-45A2-A538-C233A004DF60</gtr:id><gtr:firstName>Caroline</gtr:firstName><gtr:surname>Alvares</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500412"><gtr:id>1E0AFBF3-213B-496F-8815-2F1F59E374BE</gtr:id><gtr:title>Investigating the molecular basis of leukaemia stem cell behaviour: a project to characterise human leukaemia stem cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0500412</gtr:grantReference><gtr:abstractText>Acute myeloid leukaemia is a malignant blood disorder characterised by proliferation of immature cells in the bone marrow. The leukaemia stem cell has been implicated in disease initiation and maintenance and is a likely cause for relapse which remains a major cause of death. In addition curative treatment options such as bone marrow transplantation are not available to all patients with AML and treatment related toxicity is high. This project aims to isolate the leukaemia stem cell population from samples taken from patients with AML, after consent, and to study these cells in vitro as a basis for identifying the genes responsible for maintaining the disease. We will then aim to identify potential targets for drug design from this data and test the sensitivity of these leukaemia stem cells to a variety of drugs, in an effort to optimise current treatment strategies.</gtr:abstractText><gtr:technicalSummary>Evidence to date indicates that AML is a disease of disrupted haemopoietic differentiation resulting in the clonal proliferation of progenitor cells with aberrant transcriptional programmes. The identification of several translocations commonly found in acute leukaemia eg AML1-ETO, TEL-AML1, has provided an insight into how self-renewal and differentiation may be uncoupled to give rise to the leukaemia phenotype. Work in NODSCID mice has implicated the leukaemia stem cell population (LSC) as important for disease initiation and maintenance, and a likely determinant of relapse. In this project we will establish an in vitro model for characterising human LSC from patient samples, as a pre-requisite for studying leukaemia pathogenesis. We will use this model to identify potential therapeutic targets and assay drug sensitivity of the LSC population. Using published methods and in parallel with techniques currently working at the ICR for murine cells, we will isolate AML progenitor cells from patient samples, focusing on AML1-ETO leukaemias. Professor Greaves? group at the ICR has established working clonogenic replating assays for isolating leukaemia cells with self-renewal properties. After triplicate replating, these cells will be cultured, expanded in vitro and their immunophenotypic characteristics determined from flow cytometry. Their ability to reconstitute leukaemia will be validated using NODSCID models in collaboration with Dr Kearney?s group at the ICR. Gene expression profiles will be determined using standard in vitro transcription technology to amplify RNA followed by hybridisation to GeneChip (Affymetrix) arrays. The aims of this project are: (i) to establish an in vitro assay to enumerate AML clonogenic stem cells; (ii) to confirm their stem cell nature; (iii) to determine the immunophenotype and gene expression profile of the clonogenic cells, and (iv) to determine their response to therapeutic targeting.</gtr:technicalSummary><gtr:fund><gtr:end>2009-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>230957</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>21B0CD67-7465-47C7-929F-1183C76E44A9</gtr:id><gtr:title>Tyrosine kinase inhibitor insensitivity of non-cycling CD34+ human acute myeloid leukaemia cells with FMS-like tyrosine kinase 3 mutations.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3c0cff2c76afa8ed6f180d3f28953218"><gtr:id>3c0cff2c76afa8ed6f180d3f28953218</gtr:id><gtr:otherNames>Alvares CL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>fYLg5R4XiQV</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500412</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>